Natural products as new antimitotic compounds for anticancer drug development by Paier, Carlos Roberto Koscky et al.
Natural products as new antimitotic compounds for
anticancer drug development
Carlos Roberto Koscky Paier,I,* Sarah Sant’Anna Maranha˜o,I,II Teiliane Rodrigues Carneiro,I,III,IV Lı´dia
Moreira Lima,IV Danilo Damasceno Rocha,I Renan da Silva Santos,I,II Kaio Moraes de Farias,I,III Manoel
Odorico de Moraes-Filho,I,II,III Claudia PessoaI,II,III
I Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE,
BR. IIPrograma de Pos graduacao em Farmacologia, Universidade Federal do Ceara, Fortaleza, CE, BR. IIIPrograma de Pos graduacao em Biotecnologia, Rede
Nordeste de Biotecnologia (RENORBIO), Universidade Federal do Ceara, Fortaleza, CE, BR. IVLaboratorio de Avaliacao e Sintese de Substancias Bioativas
(LASSBio), Instituto de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, BR.
Paier CR, Maranha˜o SS, Carneiro TR, Lima LM, Rocha DD, Santos RS, et al. Natural products as new antimitotic compounds for anticancer
drug development. Clinics. 2018;73(suppl 1):e813s
*Corresponding author. E-mail: crkpaier@gmail.com
Cell cycle control genes are frequently mutated in cancer cells, which usually display higher rates of proliferation
than normal cells. Dysregulated mitosis leads to genomic instability, which contributes to tumor progression and
aggressiveness. Many drugs that disrupt mitosis have been studied because they induce cell cycle arrest and
tumor cell death. These antitumor compounds are referred to as antimitotics. Vinca alkaloids and taxanes are
natural products that target microtubules and inhibit mitosis, and their derivatives are among the most
commonly used drugs in cancer therapy worldwide. However, severe adverse effects such as neuropathies are
frequently observed during treatment with microtubule-targeting agents. Many efforts have been directed at
developing improved antimitotics with increased specificity and decreased likelihood of inducing side effects.
These new drugs generally target specific components of mitotic regulation that are mainly or exclusively
expressed during cell division, such as kinases, motor proteins and multiprotein complexes. Such small molecules
are now in preclinical studies and clinical trials, and many are products or derivatives from natural sources. In
this review, we focused on the most promising targets for the development of antimitotics and discussed the
advantages and disadvantages of these targets. We also highlighted the novel natural antimitotic agents under
investigation by our research group, including combretastatins, withanolides and pterocarpans, which show the
potential to circumvent the main issues in antimitotic therapy.
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’ INTRODUCTION
Cancer pathogenesis is a complex process in which normal
cycling cells acquire basic neoplastic characteristics typically
common to all tumor types. Cells from normal tissues exhibit
growth entirely controlled by the cell division machinery,
which is orchestrated by the production, release, recognition
and inhibition of growth-promoting signals to foster tissue
homeostasis. Tumor cells escape from this growth orchestra-
tion through various pathways, usually those linked to self-
sufficient growth. Therefore, an essential feature of cancer cells
is the ability to maintain chronically disrupted homeostatic
proliferation (1). Mitosis is the fundamental proliferation
process of division in human somatic cells; dysregulated
mitosis leads to genomic instability characterized by DNA
mutations and chromosomal aberrations. These genetic cha-
nges result in proliferative advantages for neoplastic cells and
increase the susceptibility of these cells to the accumulation
of additional genetic mutations, which in turn contribute
to tumor progression and an exacerbated aggressive pheno-
type (2).
Some compounds used in cancer chemotherapy target
protein components of the mitotic regulatory machinery,
acting as cell division blockers and, consequently, cell death
inducers (3). Many proteins involved in this process play an
essential role in mitosis, making them interesting targets for
the development of antimitotic anticancer drugs. The clinical
success of compounds that disrupt microtubule dynamics,
such as vinca alkaloids and taxanes, stimulated the devel-
opment of new drugs with specific mitotic targets (4).
Substantial research aimed at the development of new anti-
mitotic compounds with different targets and increasingly
selective antitumor activity has ensued. Herein, we discuss
traditional and novel antimitotics with antitumor potential
and the respective cellular targets of these agents, as sum-
marized in Figure 1.DOI: 10.6061/clinics/2018/e813s
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Antimitotic agents and their main targets
Mitosis is a crucial phase of the cell cycle when the chromo-
somes must be aligned on the metaphase plate and segregated
correctly to generate two identical daughter cells. The search for
new clinically effective antitumor compounds has yielded
many drugs directed at targets expressed during mitosis. Such
compounds, called antimitotics, target proteins involved in this
complex process and are mitotic arrest agents (5).
Figure 1 - Antimitotic targets and their respective inhibitors as cited in the text. The targets are placed in the illustration according to
the cell cycle phase in which they perform their main functions. The corresponding inhibitors are listed in the legend. The phases of
mitosis are depicted in blue, the phases of interphase are in green, and cell cycle checkpoints are in red. The compounds (+)2,3,9-
trimethoxypterocarpan and withaphysalin F are not included, because their targets are unknown.
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Microtubules and microtubule-associated proteins
Microtubules are composed of a- and b-tubulin hetero-
dimers that rapidly polymerize and depolymerize. Many
microtubule-associated proteins (MAPs) fine-tune the orga-
nization of microtubules and promote or suppress micro-
tubule dynamics (6). Microtubules play important roles in a
wide range of cellular functions, such as the assembly of the
mitotic spindle; the movement of organelles, vesicles and
proteins; and the associated cell signaling, as well as in the
development and maintenance of cellular shape (7). Chro-
mosome segregation is first enabled by the connection bet-
ween mitotic spindle microtubules and the kinetochore, a
macromolecular complex positioned at the chromosomal
centromere, which is assembled at the beginning of mitosis
(4). Coupling between microtubules and the kinetochore is
essential for correct spindle formation and subsequent
chromosome alignment and segregation (6). Unsurprisingly,
the first antimitotic drugs developed interfere with micro-
tubule dynamics, through either the inhibition or stabiliza-
tion of microtubule polymerization.
Tubulin-targeting antimitotics bind tubulin at different sites
and may exert different effects. Vinca alkaloids (vincristine,
vinblastine, vindesine, vinorelbine and vinflunine) are natural
products capable of binding and destabilizing the polymeric
structure of microtubules, thus causing microtubule disas-
sembly. Colchicine also acts via this mechanism but at another
interaction site. Taxanes (paclitaxel and docetaxel) and epo-
thilones are examples of microtubule-stabilizing agents that
prevent depolymerization (8). Tubulin-binding agents tradi-
tionally used in the clinic kill dividing tumor and healthy cells
and affect microtubule dynamics in nonproliferating cells,
resulting in various side effects, such as myelosuppression
and neuropathies (9). Nevertheless, tubulin-binding agents are
widely employed in the treatment of several solid tumors and
oncohematological malignancies (8).
After the first tubulin-binding agents showed antitumor
effects, many other tubulin-targeting antimitotic drugs were
developed, along with related inhibitors directed at other
targets such as kinases and mitotic protein complexes, aimed
at inhibiting cell proliferation (5). Among the MAPs, the
kinesin spindle protein (KSP) Eg5 is a kinesin responsible for
the separation of centrosomes and for the bipolar configura-
tion of the mitotic spindle. Inhibition of Eg5 causes monopolar
spindle formation and cell cycle arrest, an effect demonstrated
by monastrol, a small-molecule Eg5 inhibitor (10,11). Other
Eg5 inhibitors, such as ispinesib (Cytokinetics), SB743921
(Cytokinetics), AZD4877 (AstraZeneca), Arq621 (ArQule),
EMD-534085 (Merck-K GaA), MK-0731 (Merck & Co.),
filanesib (Array Biopharma) and litronesib (Kyowa Hakko
Kirin/Eli Lilly), have reached clinical trials (12). Centromeric
protein E (CENP-E) is another MAP inhibited by antitumor
agents. CENP-E is essential for the alignment of chromo-
somes during metaphase and passage to anaphase (3).
Examples of CENP-E inhibitors are PF-2771 (13), UA62784
(14) and Cmpd-A (15), but only GSK923295 has reached
clinical trials (16). Abnormalities in the function and exp-
ression of kinesins are important for the development
and progression of many human cancers, suggesting that
this class of proteins is an interesting target for new anti-
cancer therapy strategies (17,18). Since some kinesins are
expressed only during mitosis, their inhibition may reduce
side effects related to antineoplastic agents targeting inter-
phase proteins, such as traditional tubulintargeting antimi-
totics (9).
Cell cycle regulatory kinases
Mitosis is a strictly controlled set of events driven by many
regulatory proteins that ensure cellular modifications suita-
ble for the correct replication and distribution of genomic
DNA between daughter cells. Among the proteins targeted
by new antitumor agent prototypes are cell cycle regulators
such as checkpoint kinases (CHKs) and cyclin-dependent
kinases (CDKs), as well as regulators of the mitotic process,
including Aurora kinases (AURKs) and polo-like kinases
(PLKs) (19).
CDKs and CHKs control cell cycle progression. CHKs are
responsible for maintaining cell genomic integrity since they
are activated in response to DNA damage detected by
molecular checking mechanisms in a temporally and spa-
tially controlled manner. Activation of CHK1 and CHK2
results in cell cycle arrest, so that DNA is repaired or, if repair
is not possible, apoptosis can be triggered. The defects in
checkpoint signaling in many types of cancer are important
drivers for the development of new drugs targeting CHKs
(20). In addition, CDKs are kinases that control crucial steps
in the cell cycle and are regulated by binding proteins called
cyclins. Gene products that promote cell cycle progression
are often mutated and constitutively active in tumor cells,
increasing the interest in the development of selective
inhibitors of CDKs and mitotic kinases (21). CDK inhibitors
(CDKIs) include staurosporine, alkaloids and flavonoids,
many of which have undergone clinical studies (22,23).
PLK1 is the most studied member of the PLK family, with
important roles in some cell cycle steps, such as the
activation of the CDK1-cyclin B complex, the onset of
chromosomal segregation and cytokinesis (25). The expres-
sion of PLK1 is often elevated in tumors, which is correlated
with a poor prognosis; thus, PLK1 is a target for anticancer
therapy (26). Indeed, the development of PLK inhibitors is
currently focused on PLK1 and has resulted in two
promising inhibitors in clinical trials, namely, rigosertib and
volasertib (27,28).
The Aurora family consists of serine-threonine kinases
with a pivotal role in the control of the cell cycle and mitosis.
Aurora A is located in the centrosome and acts in the pro-
gression from the G1 phase to the S phase of the cell cycle
and in the initial stages of mitosis, enabling centrosome
separation and mitotic spindle assembly. Aurora B is found
in the mitotic spindle and controls chromosome condensa-
tion, in addition to acting at the end of mitosis to regulate
cytokinesis (29). Both Auroras have an oncogenic role in
human tumors (30-33). Among the effects associated with
tumorigenesis, Aurora A overexpression leads to chromoso-
mal instability characterized by aneuploidy and the pre-
mature segregation of sister chromatids (34). Inhibition of
Aurora kinases is a strategy in cancer treatment, especially in
combined therapeutic approaches. Most Aurora inhibitors,
such as alisertib, tozasertib and barasertib, compete with
ATP for binding to the catalytic site (35-37).
Nonmitotic targets affecting the cell
proliferation rate
Functional interphase proteins are targets that disrupt the
cell cycle and prevent mitosis via DNA repair modulation,
protein turnover and checkpoint signaling. Targeting these
nonmitotic proteins may hinder cell division. For example,
the ataxia-telangiectasia mutated (ATM) kinase induces a cell
signaling cascade in response to DNA double-strand breaks.
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When activated, ATM phosphorylates substrates that pro-
mote DNA repair and, consequently, cell cycle progression
(38). Somatic mutations in the ATM gene are found in several
cancers, especially in hematological malignancies, and are
often associated with chemotherapy resistance and unfavor-
able prognoses (39,40). Due to the substantial influence of the
ATM kinase on cell cycle progression, the development of
ATM-specific inhibitors is a good strategy in the search for
new anticancer therapies (41). For example, the ATM inhi-
bitors CP466722 and Ku55933 were identified through a cell-
based high-throughput screening assay (38).
WEE1 protein is a major tyrosine kinase involved in the
progression of the cell cycle beyond the checkpoint between
the G2 phase and mitosis (M phase), preventing entry into
the mitotic cell division process in response to persis-
tent DNA damage. High expression of this protein is often
found in cancers (colorectal cancers, breast cancers, leukemias
and other cancers) and correlates with tumor progression and
negative prognoses, despite the cell cycle-arresting activity of
WEE1 before mitosis onset (42-44). This apparent contra-
diction is not yet fully understood, and the current hypo-
thesis is that WEE1 inhibition would promote the entry of cells
with excessive DNA damage into mitosis, which would induce
cell death during the ensuing M phase. WEE1 kinase inhibitors,
e.g., AZD1775, have been studied in clinical trials, but their
use is limited because of their nonselective action (45-47).
The 26S proteasome is an important multimeric complex
responsible for the degradation of misfolded or overexpressed
proteins (48). Neoplastic cells exhibit high dependence on the
26S proteasome because of the need to eliminate defective
proteins, which are detrimental to cell cycle advancement,
resulting from the genetic instability in the tumor and the high
cell proliferation rate. The accumulation of ubiquitinated and
misfolded proteins may induce apoptosis. Therefore, the 26S
proteasome is a validated therapeutic target in oncology, with
FDA-approved inhibitors such as bortezomib (Velcades)
and carfilzomib currently in clinical use (49) for the treatment
of multiple myeloma, in which malignant cells have an abun-
dance of proteasomes (49,50).
In addition to the proteins cited above, many others may be
validated as targets for cancer therapy. A better understanding
of mitotic mediators and their role in tumorigenesis may
advance the fight against highly proliferative tumor cells.
Challenges in the search for new mitotic targets for
anticancer therapy
Many efforts have been made in the search for and devel-
opment of new antitumor compounds; however, cancer
remains a difficult-to-treat disease (51). The available anti-
mitotic therapies are somewhat successful but rarely eradicate
tumors completely and generally promote tumor resistance
and systemic toxicity (52). The selectivity of antimitotics for
tumors has long been believed to be based on the high prolif-
eration rate of cancer cells in contrast to the supposed quies-
cence or low division rate of most cells in normal tissues.
Normal and tumor cells progress through the cell cycle in
similar ways, but the higher proliferation rates of cancer cells
cause mitotic targets to be more frequently expressed in
tumors than in normal tissues, thus making neoplastic cells
more sensitive to antimitotic action (52). However, Komlodi-
Pasztor and colleagues emphasized that tumor proliferation
rates may not be as high as expected, and thus the frequency
of mitotic target expression may not be as different as expected
between tumor and nontumor cell populations. This char-
acteristic could be a reason for the lack of specificity of antimi-
totic agents such as mitosis-specific kinase inhibitors (53).
In addition to selectivity issues, antimitotic drugs acting
only on M phase-exclusive targets allow interphase cancer
cells to be refractory to treatment. In his review, Mitchison
(54) compared data from the literature and showed that 2-5%
of cells in primary tumors are in the S phase, while 40% of
cells in in vitro tumor cell cultures are in the S phase. In
addition, the doubling times of tumor cells in patients are
very long, approximately fifty times greater than those in
cell lines or animal models. Furthermore, the cell prolifera-
tion ratio varies greatly according to different cancer types,
individual patient characteristics, and the primary tumor
origin and location. Therefore, the number of neoplastic cells
in interphase is probably high enough to make a tumor
resistant to chemotherapeutics that act specifically on
exclusive mitotic targets. This fact may explain the preclinical
failure of many antimitotic compounds (52,55).
Antimitotics are considered mitosis blockers and, conse-
quently, cell death inducers. The main issue in antimitotic
therapy is that not all cells blocked in M phase will die, with
many becoming aneuploid. This alteration is a direct conse-
quence of chromosomal instability, that is, susceptibility to the
gain and/or loss of chromosomes, which generates an un-
stable karyotype. This instability promotes the acquisition of
malignant tumor characteristics as a proliferative advantage
due to the increased mutation rate in oncogenes and tumor sup-
pressor genes (55). The gain of malignant features by tumors
hinders the prediction of patient response to therapy and
facilitates the emergence of chemotherapy-resistant tumor cells.
Treatment resistance is a major problem that hinders complete
cure and limits the success of anticancer drug therapy. For
example, the differential expression of b-tubulin isoforms
has been shown to result in resistance to anti-tubulin chemo-
therapeutics such as paclitaxel, along with increasing tumor
aggressiveness (56,57). Another emerging form of taxane
resistance is the increased expression of multidrug resitance
(MDR) proteins – efflux pumps that remove cancer drugs from
the tumor cell cytoplasm – such as the ATP Binding Cassette
Subfamily B Member 1 (ABCB1 protein), P-glycoprotein and
the Multidrug resistance-associated protein 1 (MRP1) (58,59).
The side effects of antimitotics are also related to the
ubiquitous function of targets such as microtubules, which
act in mitosis, interphase and quiescence. Drugs that disrupt
microtubule function are associated with side effects such as
neurotoxicity, which may lead to irreversible neuropathies.
The current generation of antimitotic therapies in clinical
trials did not meet the expectations of reduced side effects,
even with diminished neurotoxicity (60). In fact, new side
effects were found in patients treated with antimitotics and
included hematological changes such as neutropenia (61-63).
Next, we review the novel classes of antimitotics under
preclinical investigation by our research group, which have
the potential to overcome or minimize the limitations of
current anticancer antimitotics. These molecules are synthetic
analogs of well-known microtubule-targeting agents (com-
bretastatins) and natural products with multiple or unknown
targets (withanolides and pterocarpans).
Combretastatins
The combretastatins are a potent class of natural products
first isolated by Pettit and collaborators from the bark of the
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African bush willow, Combretum caffrum (64,65). These
molecules are phenolic stilbenes that bind to the colchicine
binding site on tubulin and lead to microtubule disruption
and mitotic arrest by preventing spindle formation (66).
Among the combretastatins, combretastatin A-4 (CA-4) is a
lead compound that binds to the colchicine site and exerts
antiproliferative activity by inhibiting tubulin polymeriza-
tion. Despite its structural simplicity and potent activity, this
natural product has problems related to its low solubility in
natural biological systems and the lability of the cis-stilbene
moiety. However, CA-4 is one of the most actively researched
lead molecules in anticancer drug development programs
worldwide, and extensive studies have been conducted to
develop new CA-4 analogs to overcome the issues inherent
to CA-4 and improve its pharmacotherapeutic profile (67).
Most of the recent structural modifications introduced in
CA-4 have been based on changes in the cis olefinic bond, in-
cluding the restriction of the cis configuration by a hetero-
cyclic moiety and the replacement of this configuration by a
stable linker. These modifications can maintain the original
aromatic rings or can be associated with simultaneous altera-
tions in either ring A or ring B (68). Among the new linkers
explored to replace the cis olefinic bond of the CA-4 structure,
N-acylhydrazone (NAH) is worth mentioning. From the
synthetic and medicinal chemistry perspectives, NAH is
considered a versatile subunit, and it has been described as
a privileged structure (69). This review highlights some NAH
derivatives that perturb microtubule/tubulin dynamics and
have been synthesized by our research group using LASSBios
compounds from the Federal University of Rio de Janeiro.
Amaral et al. (70) identified a new series of CA-4 analogs
designed in light of previous structure–activity relationship
studies on CA-4 derivatives (71). Several compounds exhibit
moderate to high antiproliferative activity in tumor cells,
with IC50 values ranging between 18 and 4 nmol.L
-1. Among
these compounds, LASSBio-1586, patent number WO2013
142935A1, has emerged as a lead antitumor candidate;
LASSBio-1586 is structurally simple, able to inhibit micro-
tubule polymerization, exhibits a broad in vitro and in vivo
antiproliferative profile and has a better cytotoxic selectivity
index than the natural prototype CA-4 (70). In addition, the
antiproliferative activity was evaluated in human lympho-
cytes to determine the selectivity indexes of the LASSBio
derivatives, which were better than that of CA-4 (72). More
recently, our group described the synthesis of nine new
isosteres of LASSBio-1586, aimed at improving the cytotoxi-
city and selectivity of LASSBio-1586 (73). Among these
derivatives, LASSBio-1920 was selected as the most potent,
with IC50 values of 0.3, 9.0 and 5.0 nmol.L
-1 in the HL-60,
OVCAR-8 and HCT-8 tumor cell lines, respectively (Table 1).
LASSBio-1920 also exhibited a notable cytotoxic selectivity
index in comparison with that of CA-4 and LASSBio-1586
(Table 2, Figure 2), and its ability to modulate microtubule
polymerization was confirmed. Docking studies indicated
that LASSBio-1920 can interact with the same amino acid
residues involved in the interaction of DAMA-colchicine as a
cocrystal with b-tubulin.
Our data from structure–activity relationship studies on
combretastatins reveal that the presence of the methoxy
(OCH3) group linked at position 5 of the aromatic subunit
(ring A) is crucial for cytotoxic activity, while the OCH3 group
at position 4 is not. Concerning the aromatic rings linked to
the imine subunit (ring B) of the isostere, our data suggest a
direct relationship between the increase in lipophilicity and
the enhancement of cytotoxic activity, in agreement with pre-
vious results of Amaral et al. (70). These findings can be
explained on the basis of the improved hydrophobic interac-
tion with b-tubulin (70). The more lipophilic the group bound
to ring B is, the stronger the interaction with b-tubulin.
However, the addition of lipophilic/hydrophobic groups to
the combretastatin core should be carefully considered,
since this structural modification may impair aqueous
solubility and pharmacokinetic properties.
On the basis of the articles discussed here, we observed
that microtubules and their associated proteins are feasible
targets in drug discovery programs, particularly for the
treatment of cancer. Numerous potent CA-4 derivatives have
been developed in recent years, although very few have been
accepted for clinical studies. Therefore, further structure-
based drug discovery and optimization steps focusing on the
CA-4 molecule and its analogs should be supported and
encouraged to overcome the limitations of CA-4.
Withanolides
Withanolides are lactones based on the cholesterol-derived
ergostane molecule, with oxygen atoms enzymatically added
Table 1 - Cytotoxic activity (mean IC50±SEM) of LASSBio-1586 analogs and the CA-4 and LASSBio-1586 standards in tumor cell lines
and peripheral blood mononuclear cells (PBMCs) after 72h of treatment (IC50 values are in mmol.L
-1). SEM, standard error of the mean;
IC50, the concentration of a compound needed to reduce cell growth by 50% in vitro.
Compound HL60 (mean IC50±SEM) OVCAR-8 (mean IC50±SEM) HCT-8 (mean IC50±SEM) PBMCs (mean IC50±SEM)
LASSBio-1837 0.047±1.0 10-3 0.099±0.010 0.27±0.020 0.24±0.045
LASSBio-1839 0.34±0.028 1.26±0.24 1.08±0.25 0.51±0.020
LASSBio-1840 0.10±0.031 0.39±0.031 0.34±0.068 0.43±8.110-4
LASSBio-1917 0.074±0.018 0.55±0.37 0.48±0.032 0.71±4.010-3
LASSBio-1918 0.75±0.085 4.26±0.20 4.18±0.17 2.14±0.61
LASSBio-1919 0.081±0.029 0.31±0.19 0.33±0.019 0.33±0.086
LASSBio-1920 3.010-4±4.0 10-5 9.010-3±6.0 10-3 5.010-3±3.0 10-3 0.10±0.011
CA-4 2.210-3±3.0 10-4 5.010-4±1.0 10-4 5.0 10-3±1.010-3 3.210-3
LASSBio-1586 0.29±1.2 10-3 0.29±0.040 0.45±0.081 1.34±0.065
Table 2 - Cytotoxic selectivity index (SI), which represents the
IC50 for PBMCs/cancer cell lines after 72h of treatment. PBMCs,
peripheral blood mononuclear cells; SEM, standard error of the
mean; IC50, the concentration of a compound needed to reduce
cell growth by 50% in vitro.
Compound SI PBMC/HL-60 SI PBMC/OVCAR-8 SI PBMC/HCT-8
LASSBio-1920 333.30 11.11 20.0
LASSBio-1586 4.60 4.60 3.0
CA-4 1.45 6.40 0.60
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to carbons of the steroidal core and its side chains, thus pro-
ducing complex and unusual structures. These compounds are
secondary metabolites found in plants of the family Solana-
ceae (74) and exhibit multiple biological activities, such as
antitumor (75), cytotoxic (76), antistress (77), antifeedant (78),
immunosuppressive (79) and antimicrobial (80) activities.
One of the most heavily investigated withanolides is
withaferin A, which was originally isolated from the
medicinal plant Withania somnifera (L.) Dunal, also called
Ashwagandha or Indian ginseng. This molecule exhibits
growth-inhibitory activity in many tumor cell lines through
multiple mechanisms, including an antimitotic mode of
action. Like taxanes and vinca alkaloids, withaferin A binds to
b-tubulin, disorganizes the mitotic spindle and causes cell
cycle arrest at the G2/M phase transition in breast cancer cells
(81). This compound also impairs spindle assembly checkpoint
function (82) and alters the expression levels of mitosis-related
proteins, such as WEE1, phospho-histone H3, cyclin-dependent
kinase inhibitor 1 (p21 protein), Aurora B (83) and the
anaphase-promoting complex (APC) substrate securin (84).
Withaferin A also targets a variety of nonmitotic proteins, such
as vimentin (85), annexin II (86), heat shock protein 90 (87) and
the proteasome (88). Although these proteins function mainly
during interphase, affecting them may prevent mitosis and
inhibit cell cycle progression. The exact mechanism of action of
withaferin A is not fully understood and may encompass
different cell functions during different cell cycle phases.
Another group of withanolides called the withaphysalins
was isolated from the plant Acnistus arborescens. Members of
this group have chemical structures closely related to those
of withaferin A and have also been studied by our research
team (89-91). Rocha et al. showed that withaphysalin F and
withaferin A may have mechanisms in common because the
antiproliferative activity of withaphysalin F and its effect of
arresting cells at the G2/M phase transition were also due to
interference with microtubule polymerization (91).
Pterocarpans
Pterocarpans are compounds extracted from the plant
families Fabaceae, Leguminosae, Papilionaceae and Bitumi-
naria and comprise the second largest group of isoflavo-
noids. Pterocarpans are phytoalexins produced by plants to
defend against adversities such as resource shortages, patho-
gens and UV radiation (92). In ethnopharmacology, these
compounds are extensively used to treat different ailments.
These compounds have interesting biological activities, such
as snake antivenom (93), anti-HIV (94), anti-Trypanosoma spp.,
anti-Leishmania spp. (95), antifungal, antibiotic (96), and topo-
isomerase I-inhibiting activities (97). Pterocarpans have a
benzofuran–benzopyran tetracyclic ring system, which con-
tains two chiral centers derived from the flavonoid skeleton at
the 6a and 11a positions (96,98).
Hundreds of different pterocarpans have been discovered
through different extraction methods, and the pharmacolo-
gical activity of these pterocarpans has been tested. Since the
basic structure of these compounds is chiral, methods to
synthesize pterocarpans have been suggested, for example,
sodium borohydride reduction of 2’-hydroxy isoflavones,
Heck arylation of 2H-chromenes, Claisen rearrangement of
aryl allyl ethers, aldol condensation between phenylacetates
and benzaldehydes, 5-endo-trig radical cyclization, alkene
metathesis and many others (98). (+)2,3,9-Trimethoxypter-
ocarpan was isolated from Platymiscium floribundum in Brazil,
and the convergent syntheses of its racemic and enantiomeri-
cally pure forms was developed by Dr. M. Banwell at the
Australian National University (ANU). The synthetic route
was patented in 2012 [WO2013000054 (A1)]. The molecule
synthesized by Professor Banwell showed the same 1H NMR
spectrum as the natural product (99).
The compound (+)2,3,9-trimethoxypterocarpan has been
investigated by our research group (Figure 3) as a potential
anticancer compound (99). This molecule showed cytotoxi-
city against four leukemia cell lines (HL-60, Molt-4, Jurkat,
and K562), and the proliferation of K562 cells was blocked
after a 48-hour incubation period (at an IC50 of 0.8 mg.mL
-1)
(99,100). Flow cytometric analysis of HL-60 cells treated for
3 hours with (+)2,3,9-trimethoxypterocarpan showed the
inhibition of DNA synthesis using a bromodeoxyuridine
(BrdU) uptake assay. The pterocarpan inhibited BrdU incor-
poration by 37, 38 and 56% during the S phase at concen-
trations of 3.97, 7.95 and 15.9 mmol.L-1, respectively. After a
24-hour treatment with the same concentrations, propidium
iodide-stained HL-60 cells showed no significant membrane
damage but DNA fragmentation was seen in almost 50% of
cells permeabilized with Triton X-100. Most HL-60 cells were
arrested at the G2/M phase transition with tetraploid DNA
content after treatment with 15.9 mmol.L-1 (+)2,3,9-trimetho-
xypterocarpan. In the indirect determination of mitochon-
drial depolarization via rhodamine 123, 38.6% of the HL-60
cell population exhibited depolarized mitochondria at the
lowest treatment concentration. The results of the BrdU,
membrane integrity and DNA content experiments sug-
gested that (+)2,3,9-trimethoxypterocarpan is a cytostatic
agent, while the results of the DNA fragmentation and mito-
chondrial depolarization experiments suggested that this
pterocarpan induces apoptosis in HL-60 cells (101).
The cytostatic activity of (+)2,3,9-trimethoxypterocarpan
in leukemia cells was corroborated by immunocytochemical
experiments in the human breast adenocarcinoma cell lines
Figure 2 - Combretastatin A-4 analogs. (A) LASSBio-1586. (B) LASSBio-1920.
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MCF-7, T47D and HS58T. After treatment with 7.95 mmol.L-1
(+)2,3,9-trimethoxypterocarpan, the breast cancer cells
remained arrested in mitosis with intact actin and micro-
tubule networks. The same result was observed in nontumor
BRL3A (murine liver) cells. However, the arrangement of
microtubules was modified in most dividing cells, which
exhibited monopolar mitotic spindles. Tripolar spindles were
also observed, mainly in T47D cells (Figure 4). Such aberrant
configurations prevented the alignment of chromosomes
on the metaphase plate, blocking cell cycle progression
and, consequently, cell division. Interestingly, none of the
treated interphase cells exhibited microtubules with morpho-
logical alterations, suggesting that the effect of (+)2,3,
9-trimethoxypterocarpan is restricted to mitosis. Lamin B
labeling showed nuclear envelope disruption and confirmed
cell cycle arrest at prometaphase (102). The monastral spin-
dles observed in treated breast cancer cells resembled the
phenotype induced by monastrol treatment (103,104). Mon-
astrol impairs the acquisition of bipolarity in dividing cells
without affecting centriole duplication (105), apparently due
to its activity against the Eg5 kinesin (106).
’ CONCLUSION
Antimitotic chemotherapeutics such as Taxol (paclitaxel),
a microtubule-stabilizing agent that causes mitotic arrest, are
Figure 3 - Structure of pterocarpans isolated from Platymiscium floribundum by Falca˜o et al. (95).
Figure 4 - Formation of atypical mitotic spindles in 2,3,9-trimethoxypterocarpan-treated cells. Actin (green), tubulin (blue) and nuclei
(red) are labeled in breast carcinoma and nontumor (BRL3A) cells treated or not treated with the compound. Note the normal
arrangement of tubulin and actin fibers in the control cells; the formation of monopolar spindles in MCF-7, HS58T and BRL3A cells; and
the formation of tripolar spindles in T47D cells. Figure from Milita˜o et al. (97).
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currently successfully employed in cancer treatment (107).
Regardless of the relative success of antimitotics, however,
the death rate from cancer remains unacceptably high
worldwide, and many efforts on different fronts have been
made to improve cancer therapy (108). The reduction of
drug resistance and side effects associated with antimitotics,
such as neurotoxicity and bone marrow suppression, is a
necessary improvement (60-63). In this review, we presented
new antimitotic classes investigated by our research group
that address the main issues of current chemotherapeutics.
The combretastatin derivatives are analogs of CA-4, an
inhibitor of tubulin polymerization and microtubule forma-
tion (68). Because the functions of tubulin and microtu-
bules are not limited to mitosis, CA-4 may affect quiescent
or interphase cells, likely causing side effects in normal
tissues (109). Thus, our structure–activity relationship studies
identified structural characteristics of improved CA-4 ana-
logs. We showed that the stability issues related to the cis
stilbene nature of the combretastatin core were overcome by
the replacement of the cis olefin double bond with an NAH
framework, whose variation may result in inactive com-
pounds. We discovered that compounds with the aromatic
rings (A and B) in a trans configuration maintain tubulin-
binding activity. Last, we showed a direct relationship bet-
ween the increase in hydrophobicity and the cytotoxic effect
of CA-4 analogs. Therefore, we described combretastatin
analogs with increased cytotoxicity and selectivity toward
tumor cells that can be lead molecules for new antimitotic
agents inducing fewer side effects.
We also reviewed antimitotics derived from the natural
products withanolides and pterocarpans. Indeed, natural
sources are major sources of lead molecules and new drugs
(110) such as CA-4 and Taxol. Although the mechanism of
action of withanolides (withaphysalin F and withaferin A) is
not fully understood, the targets of these agents may be
proteins functioning in interphase, such as b-tubulin, vimen-
tin, annexin II, heat shock protein 90 and proteasome subunits
(81,85-88). Although these proteins are not mitosis-specific,
their modulation may disrupt the cell cycle. Thus, withano-
lides may have greater-than-expected activity against targets
of cancer cells in interphase (53,54), which could decrease the
development of resistance to chemotherapy.
Finally, (+)2,3,9-trimethoxypterocarpan is an antimitotic
agent that induces cell cycle arrest at the G2/M phase
transition in leukemic cells and causes the aberrant organi-
zation of mitotic spindle microtubules in breast cancer cells.
Although treatment of cells in M phase was found to result
in monopolar and tripolar mitotic spindles, cells treated
in interphase exhibited no microtubule modifications (102).
These characteristics resemble the phenotype of cells treated
with monastrol, a specific inhibitor of the kinesin motor
protein Eg5, which is expressed only during mitosis (10,11).
Such lines of evidence suggest that the target of (+)2,3,9-
trimethoxypterocarpan is a mitosis-specific protein, and
therefore, the action of this compound may be restricted to
cells in mitosis. Therefore, this compound could potentially
spare normal quiescent and interphase cells during clinical
treatment, preventing neurotoxicity, for example.
All compounds reviewed demonstrate the potential to
address important issues regarding current antimitotic-based
cancer therapy. Therefore, in vivo antitumor assays will be
performed to confirm these antimitotics as valuable lead
molecules for the development of new anticancer drugs.
However, specificity and toxicity issues concerning such
molecules may arise but can be solved by combining anti-
mitotics with other antineoplastic agents and/or monoclonal
antibodies designed to bind to surface tumor antigens. This
strategy can be implemented through direct covalent
conjugation or drug encapsulation in nanoparticles functio-
nalized with antibodies. Antibody-drug conjugates are a new
trend in anticancer research (111); this approach also spurs
the search for new and improved antimitotics.
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